We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Latest Industry Insights

Exploring the Ethical Challenges of Brain–Computer Interface Technology content piece image
Industry Insight

Exploring the Ethical Challenges of Brain–Computer Interface Technology

This article explores the current state of brain-computer interface technology and some of the ethical considerations associated with its use.
Research Collaboration Yields New Treatment Possibilities for ALS content piece image
Industry Insight

Research Collaboration Yields New Treatment Possibilities for ALS

Frank Pun discusses how scientists from Insilico Medicine identified numerous unreported potential therapeutic targets of amyotrophic lateral sclerosis using the company’s proprietary AI-enabled biological target discovery platform.
Alzheimer’s Breakthrough: A Disruptive Systemic Approach Is Poised To Demonstrate Value content piece image
Industry Insight

Alzheimer’s Breakthrough: A Disruptive Systemic Approach Is Poised To Demonstrate Value

Today’s treatments for AD are limited and unsatisfactory. This article explores a drug development effort that is taking a completely different approach – not trying to cure the disease but actually repair the damage.
Harnessing AI as a Wellness Tool for Teenagers’ Mental Health content piece image
Industry Insight

Harnessing AI as a Wellness Tool for Teenagers’ Mental Health

To learn more about Kai – an AI-powered personal guide and companion – and the potential benefits of using AI as a wellness tool for mental health, Technology Networks spoke to Alex Frenkel.
Extending the Reach of Psychedelic Therapy With Psychoplastogens content piece image
Industry Insight

Extending the Reach of Psychedelic Therapy With Psychoplastogens

Delix Therapeutics is developing non-hallucinogenic psychedelics for use as at-home medications for mental health conditions. To find out more, we spoke to the CEO, Mark Rus.
What’s the Best Way To Take 5-MeO-DMT in a Clinical Trial?  content piece image
Industry Insight

What’s the Best Way To Take 5-MeO-DMT in a Clinical Trial?

Beckley Psytech recently announced that they have dosed the first healthy volunteers in their Phase I trial of an intranasally delivered formulation of 5-MeO-DMT, named BPL-003. To find out more about their trial approach and wider research into 5-MeO-DMT, we spoke to Beckley’s chief scientific offer, Dr. Steve Wooding.
The Software Advances Powering the Next Generation of Brain Implants content piece image
Industry Insight

The Software Advances Powering the Next Generation of Brain Implants

Blackrock Neurotech, a leader in brain-computer interface (BCI) device design, recently has announced a collaboration with Venice, CA-based software developer AE Studio. To find out more, we spoke to Evan Coopersmith, AE Studio’s executive vice-president of data science.
The Impact of Funding on Longevity Research content piece image
Industry Insight

The Impact of Funding on Longevity Research

To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.
How Researchers Are Bringing Sustainability to Scientific Discovery content piece image
Industry Insight

How Researchers Are Bringing Sustainability to Scientific Discovery

Research is advancing exciting areas of science at an unprecedented pace, but the disposable materials, powered equipment and shipping associated with experiments, sample storage and transport of reagents contribute to high energy consumption and significant waste. How are researchers bringing sustainability to scientific discovery?
Behind the Scenes on the First Study To Compare the Effects of LSD and Psilocybin content piece image
Industry Insight

Behind the Scenes on the First Study To Compare the Effects of LSD and Psilocybin

A new study has compared the effects of varied doses of psilocybin and LSD for the first time. These two popular psychedelics have been of increasing interest in clinical research. Technology Networks caught up with Rob Barrow, CEO of MindMed, to discuss the findings in more detail and explore pressing issues around blinding in psychedelic drug development.


Advertisement